Poggio Francesca, Lambertini Matteo, Bighin Claudia, Conte Benedetta, Blondeaux Eva, D'Alonzo Alessia, Dellepiane Chiara, Boccardo Francesco, Del Mastro Lucia
Department of Medical Oncology, UO Oncologia Medica 2, Policlinico San Martino-IST, Genova, Italy.
Department of Medical Oncology, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium.
ESMO Open. 2018 Nov 14;3(Suppl 1):e000458. doi: 10.1136/esmoopen-2018-000458. eCollection 2018.
Breast cancer is still the most frequent cancer diagnosed in women aged ≤40 years and the primary cause of death in this age group. The management of these patients needs a dedicated approach involving a multidisciplinary team that takes into account their treatment and survivorship issues. The present review aims to provide a perspective on the many challenges associated with treatment of young women with early breast cancer. We will focus on the standard (neo)adjuvant treatment, highlighting the paucity of age-specific results about the available genomic signatures, the groundbreaking landscape of adjuvant endocrine therapy and the relevant issue of the fertility preservation.
乳腺癌仍然是40岁及以下女性中最常被诊断出的癌症,也是该年龄组的主要死因。这些患者的治疗需要一种专门的方法,涉及一个多学科团队,该团队要考虑到他们的治疗和生存问题。本综述旨在对早期乳腺癌年轻女性治疗所面临的诸多挑战提供一种观点。我们将聚焦于标准(新)辅助治疗,强调关于现有基因组特征缺乏针对特定年龄的结果、辅助内分泌治疗的开创性局面以及生育力保存的相关问题。